Table 1.
Demographic and clinical characteristics of patients with CLBP enrolled in 4 randomized, placebo-controlled trials of duloxetine treatment14–17
| Parameters | Placebo (n = 653) | Duloxetine 60 mg (n = 642) | Total (N = 1,295) |
|---|---|---|---|
| Age, years | |||
| Mean (SD) | 54.7 (13.9) | 56.0 (14.1) | 55.3 (14.0) |
| Median (min., max.) | 55.5 (18.7, 90.9) | 57.3 (19.4, 85.4) | 56.6 (18.7, 90.9) |
| Sex, n (%) | |||
| Male | 271 (41.5) | 280 (43.6) | 551 (42.5) |
| Female | 382 (58.5) | 362 (56.4) | 744 (57.5) |
| Duration of CLBP, years | |||
| Mean (SD) | 9.6 (9.5) | 9.4 (9.6) | 9.5 (9.5) |
| Median (min., max.) | 6.9 (0.4, 64.2) | 6.0 (0.5, 54.0) | 6.2 (0.4, 64.2) |
| BPI average pain score | |||
| Mean (SD) | 5.6 (1.4) | 5.6 (1.4) | 5.6 (1.4) |
| Median (min., max.) | 5.0 (1.0, 10.0) | 5.0 (2.0, 10.0) | 5.0 (1.0, 10.0) |
| Patients with MBM data,a n | 226 | 230 | 456 |
| Mean number of painful sites in past 3 months (SD) | 3.3 (2.4) | 3.6 (2.7) | 3.5 (2.5) |
| 1 (isolated CLBP), n (%) | 54 (23.9) | 51 (22.2) | 105 (23.0) |
| ≥2, n (%) | 172 (76.1) | 179 (77.8) | 351 (77.0) |
| Patients with BDI-II data,b n | 454 | 447 | 901 |
| Mean total score (SD) | 6.4 (6.9) | 6.1 (6.7) | 6.2 (6.8) |
| Median total score (min., max.) | 4.0 (0.0, 43.0) | 4.0 (0.0, 37.0) | 4.0 (0.0, 43.0) |